The 3q25 rs2305619 Polymorphism Associates With Microvascular Obstruction in STEMI

STEMI Clinical Trial

Official title:

The 3q25 rs2305619 Polymorphism is Associated With Coronary Microvascular Obstruction Following Primary Angioplasty for Acute ST-segment Elevation Myocardial Infarction

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03907722
• Other study ID #: IndonesianCRC2
• Status: Completed
• Start date: January 1, 2018
• Est. completion date: September 3, 2018

Study information

• Verified date: April 2019
• Source: Indonesian Cardiovascular Research Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The investigators enrolled 217 patients with acute STEMI undergoing primary PCI. The rs2305619 polymorphism was evaluated by real time PCR and plasma PTX3 concentration was assessed by human PTX3 ELISA kit.

Description:

The investigators enrolled 217 patients with acute STEMI undergoing primary PCI in a tertiary care academic cardiovascular center. The rs2305619 polymorphism was evaluated by real time PCR and plasma PTX3 concentration was assessed by human PTX3 ELISA kit. The primary outcome of the study was the incidence of coronary microvascular obstruction defined as thrombolysis in myocardial infarction (TIMI) grade <3 flow after primary PCI or TIMI grade 3 flow with myocardial blush grade 0 or 1. Patients were grouped based on the genotypic variants (AA, AG and GG). The primary outcome was compared among the three variants, as well as the PTX3 concentration and 30-day mortality.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 217
• Est. completion date: September 3, 2018
• Est. primary completion date: August 2, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients with acute STEMI with symptom onset <12 h and treated by primary PCI

Exclusion Criteria:

• STEMI patients who received fibrinolytic therapy

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Microvascular Coronary Artery Disease
• Myocardial Ischemia
• ST Elevation Myocardial Infarction
• STEMI

Intervention

Other:
• Long pentraxin 3
Primary PCI

Locations

Country	Name	City	State
Indonesia	Indonesian Cardiovascular Research Center	Jakarta	DKI Jakarta

Sponsors (1)

Lead Sponsor	Collaborator
Indonesian Cardiovascular Research Center

Country where clinical trial is conducted

Indonesia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of microvascular obstruction	Percentage	Immediate after pci
Secondary	Incidence of mortality	Percentage	30 days